CML

Article

Cardiovascular risk stratification feasible in CML patients treated with TKI

• Read More

Article

No margin for nonadherence in CML patients receiving imatinib

• Read More

Latest News

New trials in leukemia: Could your patient benefit?

Author:

Helen Leask

Late-phase trials are opening up for leukemia patients aged 1-65 years.

• Read More

Article

Global rise in incident CML calls for better patient management

• Read More

Article

Frontline dasatinib therapy is effective and well tolerated in older patients with CML-CP

• Read More

Article

Allo-HCT outcomes in CML patients previously treated with 2G-TKIs

• Read More

Article

CML: Better response with first-line new-generation TKI therapy vs. imatinib

• Read More

Article

Ten-year follow-up continue to support nilotinib in Japanese patients with newly diagnosed CML-CP

• Read More

Article

Need for more precise TKI dosing in real-world CML-CP patients

• Read More

Article

CML-CP: Elevated creatine kinase levels during first-line TKI treatment associated with improved survival

• Read More

Article

Risk factors associated with COVID-19 mortality in CML patients

• Read More